CRISPR Therapeutics (Tx) is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform, which enables precise changes to genomic DNA. CRISPR Tx is developing allogeneic chimeric antigen receptor T cell therapies based on its gene-editing technology and has established a portfolio of therapeutic programs across diseases including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.